Part 1 of Our AFP Intelligence Series: The Hidden Threat to Specialty Brand Revenue & Patient Care
Alternate Funding Programs have evolved into a powerful but largely invisible force in specialty pharma—reshaping patient access, distorting brand economics, and operating outside the field of view of traditional commercial analytics.
Alternate Funding Programs (AFPs) have quietly evolved from obscure employer cost-containment experiments into one of the most consequential and least understood forces reshaping specialty pharmaceutical markets today.
What began as a fringe tactic used by a small number of self-insured employers has grown into a sophisticated, multi-billion-dollar ecosystem. Today, AFPs operate through a network of third-party vendors, specialty pharmacies, and benefit consultants—working in a gray zone that simultaneously pressures manufacturer revenue, destabilizes patient assistance programs, and introduces hidden friction into the patient journey.
This blog is the first in Phluence’s AFP Intelligence Series, where we’ll examine how AFPs work, why they are so difficult to detect, and what they mean for patient access, brand economics, and the future of specialty market access.
What Are Alternate Funding Programs?
At their core, AFPs are designed to remove specialty drug costs from employer-sponsored health plans.
They do this by redirecting commercially insured patients into manufacturer-funded assistance pathways—primarily Patient Assistance Programs (PAPs) and independent charitable foundations. These programs were originally created to support uninsured or underinsured patients. AFPs repurpose them as an alternate funding mechanism for patients who, under normal circumstances, would be covered commercially.
From the employer’s perspective, the value proposition is clear: eliminate high-cost specialty-drug spending while maintaining access to therapy.
From the manufacturer’s perspective, however, the implications are more complex.
Patients who would otherwise generate commercial revenue are instead served through free goods or assistance pathways—often without visibility into how they arrived there.
Why AFPs Emerged
To understand why AFPs took hold, it is necessary to understand the economic pressures that shaped them.
Over the past two decades, specialty pharmaceuticals—including biologics, oncology therapies, gene therapies, and rare disease treatments—have seen dramatic increases in cost. Annual therapy prices of $50,000 to $500,000 or more are no longer uncommon.
For self-insured employers, this creates a concentrated financial risk. A single patient requiring a high-cost therapy can materially impact the total cost of a health benefits plan.
AFPs emerged in the early 2010s as a response to that pressure.
The foundational insight was simple: manufacturers already fund robust assistance programs. If commercially insured patients could be routed into those programs, the employer could avoid paying for the drug altogether. What began as a practical response to rising specialty costs quickly proved scalable—and increasingly attractive to employers seeking predictable cost control.
From Workaround to Engineered System
Early AFPs were relatively manual. Vendors identified patients receiving high-cost therapies and redirected them to PAPs or foundation programs, effectively shifting costs away from the employer.
Over time, that model scaled and matured.
- 2011–2015: Early AFP Era — Small-scale, manual diversion to manufacturer PAPs, primarily among large employers.
- 2016–2019: Growth Phase — Expansion of the vendor ecosystem, introduction of automated eligibility screening, and broader reach across therapeutic categories.
- 2020–2022: Maturation Phase — Integration with specialty pharmacies, use of algorithms, and hybrid routing across PAP and foundation pathways.
- 2023–Present: Current Era — AI-driven patient identification, real-time benefit coordination, accumulator integration, and increasingly adversarial dynamics with manufacturers.
Today’s AFP is no longer a workaround. It is an orchestrated system designed to identify eligible patients, redirect their access pathway, and systematically shift financial responsibility.
AFP Trends and Their Impact
The significance of AFPs lies not just in how they work, but in how quickly they are expanding and how early they influence the patient journey.
Several trends are accelerating their impact:
- Earlier patient interception — AFP vendors are increasingly using machine learning and real-time claims data to identify patients within days of a new prescription—often before the first fill occurs.
- Expansion beyond ultra-high-cost therapies — What began with six-figure biologics is now extending into mid-tier specialty drugs.
- Reactive manufacturer response — Countermeasures remain fragmented and reactive.
- Growing regulatory scrutiny — State-level attention is increasing while federal oversight remains limited.
- New pressure from ultra-high-cost therapies — Gene therapies priced between $1M–$4M are accelerating AFP incentives.
As AFPs become more sophisticated and more deeply embedded in the access pathway, their impact becomes harder, not easier, to see.
A Problem Hiding in Plain Sight
One of the most challenging aspects of AFPs is not just their scale but also the fact that their operations and impact often go undetected.
Commercially insured patients are being served through non-commercial pathways. Manufacturer-funded programs are absorbing costs they were not designed to carry. The signals that brand teams rely on to understand performance are increasingly misaligned with reality.
Without a clear line of sight into these dynamics, brand teams are left making decisions based on an incomplete picture of both performance and patient experience.
What Comes Next in This Series
Addressing the effects of AFPs requires increased awareness and a deeper understanding of how they operate.
In the blogs that follow, we will explore:
- How modern AFPs operate in detail
- The hidden impact on patient experience
- The implications for gross-to-net and commercial analytics
- The strategies manufacturers can deploy to detect and respond
The first step in addressing AFPs is seeing them clearly. For many specialty brands today, the question is no longer whether AFPs are affecting performance—but how much of that impact remains invisible.
